Prevalence and risk factors of hepatitis A among blood donors in Qazvin, central Iran

Singapore Medical Journal

Volumn 52, Issue 2, 2011, Pages 107-112

  Ramezani, H ^a   Bozorgi, S H ^a   Nooranipour, M ^b   Mostajeri, A ^a   Kargar Fard, H ^a   Molaverdikhani, S ^a   Mazdaki, A ^a   Alavian, S M ^b  

^a Iran Blood Transfusion Organisation Research Centre   (Iran)

^b Baqiyatallah Medical Sciences University Baqyatallah Hospital   (Iran)

Author keywords

Blood donors; Hepatitis a virus; Iran; Prevalence; Risk factors

Indexed keywords

HEPATITIS A ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PREVALENCE; RISK FACTOR; SEROLOGY;

ADOLESCENT; ADULT; BLOOD DONORS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DEVELOPING COUNTRIES; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VIRUS; HUMANS; IRAN; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 79958238850     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ashur Y, Adler R, Rowe M, Shouval D. Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults. Vaccine 1999; 17:2290-6.
2. Alavi Moghaddam M. Hepatitis A virus: a major global public health problem, especially in developing countries. Hepat Mon 2005; 5:145-9.
3. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996; 45:1-30.
4. Alavian SM. Iraq: a hot zone for HAV infection? Hepat Mon 2005; 5:53-6.
5. Sherlock S, Dooley J. Diseases of the liver and biliary system. 11th ed. Oxford: Blackwell, 2002: 273-6.
6. Hepatitis A. World Health Organization, Department of Communicable Disease Surveillance and Response (CSR):1-39. Available at: www.who.int/csr/disease/hepatitis/HepatitisA_whocdscsredc2000_7.pdf. Accessed May 8, 2009.
7. Sohn YM, Rho HO, Park MS, et al. The changing epidemiology of hepatitis A in children and the consideration of active immunization in Korea. Yonsei Med J 2000; 41:34-9.
8. Hollinger FB, Ticehurst JR. Hepatitis A virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven, 1996: 735-82.
9. Shapiro CN, Margolis HS. Worldwide epidemiology of hepatitis A virus infection. J Hepatol 1993; 18 Suppl 2:S11-4.
10. Saberifiroozi M, Serati AR, Taghvaee T, Marooofi GR, Shirazi KM. Prevalence of hepatitis A virus antibodies in patients with chronic liver disease in Shiraz, Iran. Indian J Gastroenterol 2005; 24:33-4.
11. Mehr AJ, Ardakani MJ, Hedayati M, et al. Age-specific seroprevalence of hepatitis A infection among children visited in pediatric hospitals of Tehran, Iran. Eur J Epidemiol 2004; 19:275-8.
12. Ataei B, Javadi AA, Nokhodian Z, et al. HAV in Isfahan province: a population-based study. Trop Gastroenterol 2008; 29:160-2.
13. Dutta AK, Aggarwal A, Kapoor AK, Ray GN, Batra S. Seroepidemiology of hepatitis A in Delhi. Indian J Pediatr 2000; 67:77-9.
14. Erdogan MS, Otkun M, Tatman-Otkun M, Akata F, Ture M. The epidemiology of hepatitis a virus infection in children, in Edirne, Turkey. Eur J Epidemiol 2004; 19:267-73.
15. Yapicioglu H, Alhan E, Yildizdas D, Yaman A, Bozdemir N. Prevalence of hepatitis A in children and adolescents in Adana, Turkey. Indian Pediatr 2002; 39:936-41.
16. Atabek ME, Fyndyk D, Gulyuz A, Erkul I. Prevalence of anti-HAV and anti-HEV antibodies in Konya, Turkey. Health Policy 2004; 67:265-9.
17. Yassin K, Awad R, Tebi A, Queder A, Laaser U. The epidemiology of hepatitis A infection in Palestine: a universal vaccination programme is not yet needed. Epidemiol Infect 2001; 127:335-9.
18. Antaki N, Kebbewar MK. Hepatitis A seroprevalence rate in Syria. Trop Doct 2000; 30:99-101.
19. Junquera S, Mateos M, Lasa E, Chacon J, Baquero F.[Seroepidemiologic study of hepatitis A in the community of Madrid during the year 2002]. Enferm Infecc Microbiol Clin 2004; 22:448-51. Spanish.
20. Crofts N, Cooper G, Stewart T, et al. Exposure to hepatitis A virus among blood donors, injecting drug users and prison entrants in Victoria. J Viral Hepat 1997; 4:333-8.
21. Henriques I, Monteiro F, Meireles E, et al. Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors. Transfus Apher Sci 2005; 33:305-9.
22. Ibarra H, Riedemann S, Prado V, et al. [Current status of immunity to hepatitis A virus in various adult groups]. Rev Med Chil 1999; 127:1165-8. Spanish.
23. Kanda D, Takagi H, Hashimoto Y, et al. Severe manifestation of acute hepatitis A recently found in Gunma, Japan. J Gastroenterol 2002; 37:517-22.
24. Prikazsky V, Olear V, Cernoch A, Safary A, Andre FE. Interruption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol 1994; 44:457-9.
25. Boyles S. Day care setting ideal place for vaccination. Pediatrics (HAV). Vaccine Wkly 1996; 22:14-5.
26. Kaic B, Borcic B, Ljubicic M, Brkic I, Mihaljevic I. Hepatitis A control in a refugee camp by active immunization. Vaccine 2001; 19:3615-9.
27. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B virus infection in Iran: a systematic review. Hepat Mon 2008; 8:281-94.
28. Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults. Hepatology 2003; 37:44-51.